Form 4: Lexeo Therapeutics Executive Receives Stock Grant
Insider Transaction (Form 4)
Narinder Pal Bhalla, Chief Medical Officer of Lexeo Therapeutics, Inc., reported multiple transactions in common stock on September 24, 2026.
Summary
- Grant/award: acquired 2,714 Common Stock at $3.58 ($9,713) on September 14, 2026; holds 84,908 after (Direct).
- Grant/award: acquired 54,750 Stock Option (right to buy) on September 24, 2026; holds 54,750 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Narinder Pal Bhalla — Officer (Chief Medical Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-09-14 | Grant/award | Common Stock | 2,714 | $4 | $9.7K | 84,908 |
| 2026-09-24 | Grant/award | Stock Option (right to buy) | 54,750 | — | — | 54,750 |
Key Dates
| Date | Description |
|---|---|
| 2026-09-14 | Grant/award (2,714 shares) |
| 2026-09-24 | Grant/award (54,750 shares) |
Keywords
insider transaction, Form 4, LXEO, Lexeo Therapeutics, Inc., neutral, Narinder Pal Bhalla
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.